Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments

12th March, 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf

Glycostem and Ghent University sign license agreement on NK cell therapy technology

17th December, 2020 - Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an inn

Glycostem announces treatment of first patient in pivotal phase I/IIa trial

15th December, 2020 – Glycostem today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord® for th

Glycostem initiates phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia

20th November 2020 – Glycostem today announced the

FDA grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma

12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.

Glycostem collaborates with LUMICKS

30th July, 2020 - LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development.

Glycostem enters contract with Autolomous to digitise manufacturing process

3rd June, 2020 – Autolomous Ltd, a leading edge developer of innovative digital solutions for manufacture of advanced medicines, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company, today a

Glycostem partners with Zelluna Immunotherapy

19th November, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment  of  multiple  solid  cancers, and Glycostem Therapeutics BV,  a  clinical  stage  and leading Natural Killer (NK) cell manufacturing company, today announce that they have entered  into  a  de

Glycostem welcomes Dr Rizwan Romee as US based advisor

12th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK cell company,today announced to have welcomed Rizwan